The Syk Inhibitor Entospletinib Abolishes Dermal –Epidermal Separation in a Fully Human Ex Vivo Model of Bullous Pemphigoid
Bullous pemphigoid (BP) is an autoantibody-mediated blistering skin disease characterized by local inflammation and dermal –epidermal separation, with no approved targeted therapy. The Syk tyrosine kinase is critical for various functions of the immune response. Second-generation Syk inhibitors such as entospletinib are currently being tested for hematological malignancies. Our aim was to test the effect of entospleti nib in a fully human model system of BP. Incubating BP serum–treated human frozen skin sections with normal human granulocytes and fresh plasma triggered dermal–epidermal separation that was dependent o...
Source: Journal of Investigative Dermatology - January 29, 2024 Category: Dermatology Authors: Simon Vik ár, Kata P. Szilveszter, Kamilla Koszorú, Miklós Sárdy, Attila Mócsai Tags: Original Article Source Type: research
Clinical Features of Paediatric Inflammatory Epidermolysis Bullosa Acquisita: A Case Series Study
In conclusion, EBA in childhood may be unique, and thus distinct from its adult counterpart. Specific treatment and follow-up protocols are required for therapy of this rare autoimmune skin disease in children.PMID:38270257 | PMC:PMC10831865 | DOI:10.2340/actadv.v104.11917 (Source: Acta Derm Venereol A...)
Source: Acta Derm Venereol A... - January 25, 2024 Category: Dermatology Authors: Yuexin Zhang Jingyang Dang Ruoyu Li Xixue Chen Xuejun Zhu Mingyue Wang Source Type: research
Metformin adverse event profile: a pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) from 2004 to 2022
CONCLUSION: Most of our results were consistent with the specification, but some new signals of adverse reactions such as acute pancreatitis were not included. Therefore, further studies are needed to validate unlabeled adverse reactions and provide important support for clinical monitoring and risk identification of metformin.PMID:38269492 | DOI:10.1080/17512433.2024.2306223 (Source: Expert Review of Clinical Pharmacology)
Source: Expert Review of Clinical Pharmacology - January 25, 2024 Category: Drugs & Pharmacology Authors: Yikuan Du Jinfeng Zhu Zhuoming Guo Zhenjie Wang Yuni Wang Mianda Hu Lingzhi Zhang Yurong Yang Jinjin Wang Yixing Huang Peiying Huang Mianhai Chen Bo Chen Chun Yang Source Type: research
Clinical Features of Paediatric Inflammatory Epidermolysis Bullosa Acquisita: A Case Series Study
In conclusion, EBA in childhood may be unique, and thus distinct from its adult counterpart. Specific treatment and follow-up protocols are required for therapy of this rare autoimmune skin disease in children.PMID:38270257 | PMC:PMC10831865 | DOI:10.2340/actadv.v104.11917 (Source: Acta Dermato-Venereologica)
Source: Acta Dermato-Venereologica - January 25, 2024 Category: Dermatology Authors: Yuexin Zhang Jingyang Dang Ruoyu Li Xixue Chen Xuejun Zhu Mingyue Wang Source Type: research
Upadacitinib for the management of bullous pemphigoid coexisting with psoriasis vulgaris: a case report and literature review
J Dermatolog Treat. 2024 Dec;35(1):2302394. doi: 10.1080/09546634.2024.2302394. Epub 2024 Jan 23.ABSTRACTBoth bullous pemphigoid (BP) and psoriasis are common immune-related dermatological conditions in clinical practice, but the co-occurrence of these two diseases is rare. Currently, there is no consensus on the long-term safe and effective treatment for patients with both BP and psoriasis. JAK inhibitors are emerging as targeted therapeutic drugs that act by inhibiting Janus kinase activity, regulating the JAK/STAT pathway, blocking the transduction pathway of key proinflammatory cytokines, and influencing T-cell differe...
Source: Journal of Dermatological Treatment - January 24, 2024 Category: Dermatology Authors: Fangying Su Tai Wang Qunshi Qin Zhi Xie Source Type: research
Omalizumab used to treat bullous pemphigoid resistant to other treatments
Br J Dermatol. 2024 Jan 23;190(2):e23. doi: 10.1093/bjd/ljad510.NO ABSTRACTPMID:38262596 | DOI:10.1093/bjd/ljad510 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - January 23, 2024 Category: Dermatology Source Type: research
Proteomic changes related to actin cytoskeleton function in the skin of vildagliptin-treated mice
Vildagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i) is a widely used type 2 diabetes medication that is associated with an up-to 10-fold increased risk for the development of bullous pemphigoid (BP), an autoimmune skin disease. The mechanism by which vildagliptin promotes the development of BP remains unknown. (Source: Journal of Dermatological Science)
Source: Journal of Dermatological Science - January 20, 2024 Category: Dermatology Authors: Antti N ätynki, Nina Kokkonen, Jussi Tuusa, Steffen Ohlmeier, Ulrich Bergmann, Kaisa Tasanen Source Type: research
Risk and determinants of herpes zoster in bullous pemphigoid: a large-scale population-based study
(Source: Archives of Dermatological Research)
Source: Archives of Dermatological Research - January 18, 2024 Category: Dermatology Source Type: research
Linear IgA bullous dermatosis associated with immunotherapy
We present the case of a 67-year-old woman with metastatic ovarian cancer receiving anti-PD1 and anti-CTLA4 with new onset pruritic tense bullae to the trunk, hands, elbows (in annular distribution) that occurred after immunotherapy. Skin biopsy showed subepidermal blister with abundant neutrophils on H&E histology, and linear IgA staining at the basement membrane on direct immunofluorescence consistent with the diagnosis of LABD. The condition did not improve on initial prednisone taper, but blisters rapidly resolved a few days after initiation of dapsone... (Source: Dermatology Online Journal)
Source: Dermatology Online Journal - January 18, 2024 Category: Dermatology Authors: Momin, Bahar Source Type: research
Risk and determinants of herpes zoster in bullous pemphigoid: a large-scale population-based study
(Source: Archives of Dermatological Research)
Source: Archives of Dermatological Research - January 18, 2024 Category: Dermatology Source Type: research
Inflammatory conditions of the oral mucosa
Inflammatory mucocutaneous conditions that affect the oral cavity are wide ranging with overlapping clinical and histological features. Clinically these can present with a range of appearances including lace to plaque like patches to erosive and ulcerative conditions. Many of these conditions are associated with systemic affects including gastrointestinal, ocular and dermatological. Early recognition is essential to ensure optimal patient care and appropriate referral to other specialists. This review will concentrate on lichenoid mucositis including lichen planus and erythema multiforme, the vesiculo-bullous conditions pe...
Source: Diagnostic Histopathology - January 12, 2024 Category: Pathology Authors: Philip A Atkin, Syed A Khurram, Adam V Jones Tags: Mini-symposium: head and neck pathology Source Type: research
Comparison of gut microbiota dysbiosis between pemphigus vulgaris and bullous pemphigoid
CONCLUSIONS: Our study suggests that the composition of gut microbiota is specific in different bullous diseases and the role of gut microbiota differs. Gut microbiota could help distinguish BP and PV, and might play a role in the pathogenesis of different bullous diseases.PMID:38185033 | DOI:10.1016/j.intimp.2023.111470 (Source: International Immunopharmacology)
Source: International Immunopharmacology - January 7, 2024 Category: Allergy & Immunology Authors: Ziying Han Yue Fan Qingyang Wu Feng Guo Sizhe Li Xiaomin Hu Ya-Gang Zuo Source Type: research
Bullous pemphigoid, malignant acanthosis nigricans, and erysipeloid carcinoma in a woman with gastric adenocarcinoma
Key Clinical MessageBullous pemphigoid did not follow the course of Gastric Carcinoma relapse and remisson, unlike the malignant acanthosis nigricans which was in alignment with the paraneoplastic effect of the Gastric Carcinoma.AbstractAcanthosis nigricans (AN) is a dermatosis characterized by the presence of hyperpigmented, velvety cutaneous thickening in the flexural areas, posterior neck, and occasionally the extensor surfaces of hand, face, and oral mucosa. AN is commonly associated with insulin resistance, drugs, and rarely internal malignancy (malignant AN). Bullous pemphigoid (BP) is an autoimmune blistering diseas...
Source: Clinical Case Reports - January 3, 2024 Category: General Medicine Authors: Saman Al ‐Zahawi,
Yasaman Sadeghi,
Vahidesadat Azhari,
Hamidreza Mahmoudi,
Maryam Daneshpazhooh Tags: CASE REPORT Source Type: research
Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update
AbastractBullous pemphigoid (BP) is a common autoimmune bullous disease affecting mainly the elderly, with rising incidence due to increased life expectancy. This disease is characterized by tense bullous lesions on normal or erythematous skin, accompanied by pruritus. BP pathogenesis involves autoantibodies against hemidesmosomal proteins BP180 and BP230, leading to detachment at the dermo-epidermal junction as well as blister formation. BP is associated with coexisting comorbidities and drug exposure, and its management often requires high doses or chronic use of systemic glucocorticoids, posing risks of adverse effects....
Source: American Journal of Clinical Dermatology - December 29, 2023 Category: Dermatology Source Type: research
Potential Indications of Dupilumab in Th-2 Inflammatory Disease
Rev Recent Clin Trials. 2023 Dec 20. doi: 10.2174/0115748871263396231121060901. Online ahead of print.ABSTRACTDupilumab is a fully humanized IgG4 monoclonal antibody, inhibiting IL-4 and IL-13 signaling, which are the main cytokines involved in type 2 inflammatory diseases. Its introduction was a breakthrough in the treatment of moderate-to-severe atopic dermatitis, but it is also used in other inflammatory diseases, including asthma, eosinophilic esophagitis and chronic rhinosinusitis with nasal polyposis. Recent advances in the understanding of inflammatory pathways have revealed that Th2-type inflammation is involved in...
Source: Reviews on Recent Clinical Trials - December 23, 2023 Category: Cancer & Oncology Authors: Proietti Ilaria Skroza Nevena Tolino Ersilia Bernardini Nicoletta Federica Trovato Marco Di Fraia Dybala Agniezska Potenza Concetta Source Type: research
